8-K: Iterum Therapeutics to Delist Amid Winding Up Petition

Iterum Therapeutics plc announced its ordinary shares will be delisted from Nasdaq and trading suspended on April 1, 2026, following the company's decision to withdraw its appeal and file a winding up petition in Ireland.

Summary

• Iterum Therapeutics plc's ordinary shares will be delisted from The Nasdaq Capital Market.
• Trading of the company's ordinary shares will be suspended at the opening of business on April 1, 2026.
• The delisting follows the company's withdrawal of its appeal against a prior delisting determination due to failure to maintain a minimum bid price of $1.00 per share.
• The company filed a petition in the High Court in Ireland on March 27, 2026, to wind up the company.
• Due to limited cash resources and the ongoing winding up process, the company does not expect to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, or any other future filings with the SEC.

Sentiment

Score: 1

Explanation: StockSavvy.ai views this as an extremely negative development, indicating the company's effective failure and impending dissolution, with minimal to no value likely remaining for shareholders.

Negatives

• Delisting of ordinary shares from Nasdaq.
• Suspension of trading on Nasdaq effective April 1, 2026.
• Filing of a petition to wind up the company in the High Court in Ireland.
• Cessation of future SEC filings, including the Annual Report on Form 10-K for fiscal year ended December 31, 2025.
• Limited cash resources.

Risks

• Uncertainty regarding the approval by the Irish High Court of the Winding Up Petition.
• Risks and uncertainties concerning the company's ability to effect an orderly winding up of its business.
• Uncertainty regarding the timing of delisting of the company's ordinary shares from Nasdaq.
• Potential proceedings that may be brought by third parties in connection with the petitions or the potential sale of all or some of the company's assets.
• Uncertainty regarding obtaining the Irish High Court's approval of the potential sale of all or some of the company's assets or other terms and conditions to any such potential sale.
• Uncertainties regarding the ability of shareholders and other stakeholders to realize any value or recovery as part of the winding up process.
• Risks resulting from the company's expectation that it will no longer file reports with the SEC.

Future Outlook

The company expects its ordinary shares to be delisted from Nasdaq and trading suspended on April 1, 2026. It also anticipates not filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, or any other future SEC filings, due to limited cash resources and the ongoing winding up process. The winding up process itself is subject to approval by the Irish High Court.

Management Comments

• "Given the Company’s limited cash resources and the ongoing winding up process by Damien Murran and Jennifer McMahon of Teneo Restructuring (Ireland) Limited as the joint provisional liquidators, the Company does not expect to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 or make any other future filings with the Securities and Exchange Commission."
• "The joint provisional liquidators are signing this report in their capacity as provisional liquidators of the Company only. Any personal liability is expressly excluded and their firm shall be under no liability affecting them personally or their estate."

Industry Context

StockSavvy.ai notes that delisting from major exchanges like Nasdaq and initiating winding-up proceedings are severe indicators of financial distress, often seen in smaller biotechnology or pharmaceutical companies that fail to bring products to market or secure sufficient funding. This event highlights the high-risk nature of early-stage drug development and the critical importance of maintaining financial viability and regulatory compliance for continued public listing.

Comparison to Industry Standards

• This situation is a clear deviation from industry standards, where publicly traded companies are expected to maintain minimum listing requirements and ongoing financial reporting.
• There are no comparable positive projects or results; instead, this reflects a failure to meet basic operational and financial benchmarks, leading to the company's effective dissolution.

Management Changes

Corporate Governance

Legal Proceedings

• A petition was filed in the High Court in Ireland on March 27, 2026, to wind up the company.
• The company previously requested a hearing before a Nasdaq Hearings Panel regarding a delisting determination, but subsequently withdrew its appeal.

Stakeholder Impact

• Shareholders: Highly negative impact, as shares will be delisted, trading suspended, and there is uncertainty regarding the ability to realize any value or recovery from the winding up process.
• Creditors: The winding up process will prioritize creditor satisfaction, but the outcome depends on the realization of assets.
• Employees: Implied significant negative impact due to the winding up of the company, likely leading to job losses.
• Customers/Suppliers: Operations are ceasing, so existing relationships will be terminated.

Next Steps

• Trading of ordinary shares will be suspended on Nasdaq at the opening of business on April 1, 2026.
• A Form 25-NSE will be filed with the SEC to remove the company's ordinary shares from listing on Nasdaq.
• The winding up process, initiated by the petition in the High Court in Ireland, will continue.
• The joint provisional liquidators will manage the winding up process.
• The company does not expect to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, or any other future SEC filings.

Key Dates

Recommendation

The company is undergoing a winding-up process, its shares are being delisted from Nasdaq, and it will cease all public reporting. This indicates a complete failure of the business and a high probability of minimal to no recovery for shareholders. Investors should exit any remaining positions immediately.

Keywords

Iterum Therapeutics, ITRM, Nasdaq delisting, winding up, liquidation, SEC filing cessation, biotechnology, pharmaceuticals, corporate governance, risk management